About kezar life sciences inc - KZR
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 19, 2015 and is headquartered in South San Francisco, CA.
KZR At a Glance
Kezar Life Sciences, Inc.
4000 Shoreline Court
South San Francisco, California 94080
| Phone | 1-650-822-5600 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -83,736,000.00 | |
| Sector | Health Technology | Employees | 55 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
KZR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.42 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.761 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.241 |
KZR Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,522,472.727 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
KZR Liquidity
| Current Ratio | 6.763 |
| Quick Ratio | 6.763 |
| Cash Ratio | 6.505 |
KZR Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -45.768 |
| Return on Equity | -55.002 |
| Return on Total Capital | -62.914 |
| Return on Invested Capital | -51.083 |
KZR Capital Structure
| Total Debt to Total Equity | 13.839 |
| Total Debt to Total Capital | 12.157 |
| Total Debt to Total Assets | 11.183 |
| Long-Term Debt to Equity | 6.361 |
| Long-Term Debt to Total Capital | 5.588 |